The availability of emicizumab (Hemlibra) means that prophylaxis can now be offered for previously untreated infants with severe haemophilia A (SHA) without inhibitors, according to haematologists in Queensland. The monoclonal inhibitor product has been licensed for use in patients of all ages with SHA, but haematologists may have to make important treatment decisions for infants ...
Australian experience highlights advantages of emicizumab in infants with SHA, despite lack of data
By Michael Woodhead
17 Jun 2021